Suppr超能文献

玻璃体内细胞因子水平变化与糖尿病黄斑水肿眼内注药后视网膜血管变化的关系

Relationship between aqueous humor cytokine level changes and retinal vascular changes after intravitreal aflibercept for diabetic macular edema.

机构信息

Department of Neuroscience, Polytechnic University of Marche, Ancona, 60126, Italy.

Eye Clinic, Department of Medicine, Surgery and Health Sciences, University of Trieste, Trieste, 34100, Italy.

出版信息

Sci Rep. 2018 Nov 8;8(1):16548. doi: 10.1038/s41598-018-35036-9.

Abstract

The aim of this work was to investigate the changes in aqueous humor cytokine levels after intravitreal injection of aflibercept in diabetic macular edema (DME) and to evaluate the relationship between cytokines modifications and central macular thickness (CMT) and retinal/choroidal vascular changes using structural and functional optical coherence tomography (OCT). Aqueous concentrations of 38 cytokines were measured via multiplex bead assay. In addition, spectral domain OCT and OCT angiography with SSADA software (XR Avanti® AngioVue) were performed at baseline and after intravitreal injections. VEGF, IL-6, IL-5, IL-1β, Eotaxin, GRO, IL-12p40, IL-12p70, IL-1RA, Flt-3L and IP-10 showed a statistically significant decrease through the follow-up (p < 0.05; p < 0.001), while Fraktalkine and GM-CSF significantly increased (p < 0.05). Best corrected visual acuity significantly increased and CMT significantly decreased during follow-up (p < 0.001 and p = 0.013). Superficial capillary plexus and deep capillary plexus density significantly increased (p < 0.001 and p = 0.014). A positive relation was found between GRO, VEGF, Fraktalkine, IP-10, IL-12p70 aqueous humor levels and CMT (p < 0.05; p < 0.001). Aflibercept is a primary anti-VEGF treatment producing a decrease of DME due to the reduction of vascular permeability, nevertheless other inflammatory cytokines showed modification after aflibercept intravitreal injections probably related to edema modification or to an interaction of aflibercept with other inflammatory cytokines.

摘要

本研究旨在探讨玻璃体内注射阿柏西普(aflibercept)治疗糖尿病黄斑水肿(DME)后房水中细胞因子水平的变化,并通过结构和功能光学相干断层扫描(OCT)评估细胞因子变化与中心黄斑厚度(CMT)和视网膜/脉络膜血管变化之间的关系。采用多重微珠检测法测定 38 种细胞因子的房水浓度。此外,在基线和玻璃体内注射后,分别进行频域 OCT 和 SSADA 软件(XR Avanti® AngioVue)的 OCT 血管造影检查。VEGF、IL-6、IL-5、IL-1β、Eotaxin、GRO、IL-12p40、IL-12p70、IL-1RA、Flt-3L 和 IP-10 在随访过程中呈显著下降(p<0.05;p<0.001),而 Fraktalkine 和 GM-CSF 则显著增加(p<0.05)。最佳矫正视力在随访过程中显著提高,CMT 显著降低(p<0.001 和 p=0.013)。浅层毛细血管丛和深层毛细血管丛密度显著增加(p<0.001 和 p=0.014)。GRO、VEGF、Fraktalkine、IP-10 和 IL-12p70 房水水平与 CMT 呈正相关(p<0.05;p<0.001)。阿柏西普是一种主要的抗 VEGF 治疗药物,可通过降低血管通透性来减少 DME,但玻璃体内注射阿柏西普后,其他炎症细胞因子也发生了变化,这可能与水肿的减轻或阿柏西普与其他炎症细胞因子的相互作用有关。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1814/6224583/d7caf171abad/41598_2018_35036_Fig1_HTML.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验